Analyst Reco. Veru Inc.

Equities

VERU

US92536C1036

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
1.27 ^USD	+4.96%		-3.05%	+76.39%

Apr. 15	Oppenheimer Cuts Veru Price Target to $5 From $7, Maintains Outperform Rating	MT
Apr. 01	Veru Inc. Reports Earnings Results for the First Quarter Ended December 31, 2023	CI

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Oppenheimer Cuts Veru Price Target to $5 From $7, Maintains Outperform Rating	Apr. 15	MT
Raymond James Starts Very With Outperform Rating, $3 Price Target	Mar. 28	MT
Oppenheimer Adjusts Veru Price Target to $7 From $9, Maintains Outperform Rating	23-08-14	MT
HC Wainwright Adjusts Price Target on Veru to $2 From $6, Maintains Buy Rating	23-05-15	MT
HC Wainwright Lowers Veru's Price Target to $6 From $14, Keeps Buy Rating	23-04-06	MT
Oppenheimer Adjusts Veru Price Target to $9 From $14, Maintains Outperform Rating	23-03-15	MT
Atlanta Fed President's Comments on Rate Hikes Continue to Boost Sentiment, Driving Cautious Gains for US Equity Futures	23-03-03	MT
Oppenheimer Adjusts Veru's Price Target to $14 From $20, Maintains Outperform Rating	23-02-14	MT
HC Wainwright Adjusts Price Target on Veru to $14 From $18, Maintains Buy Rating	23-02-10	MT
HC Wainwright Lowers Price Target on Veru to $18 From $21, Maintains Buy Rating	22-12-07	MT
HC Wainwright Cuts Price Target on Veru to $21 from $24, Keeps Buy Rating	22-11-10	MT
FDA staff flags several uncertainties with Veru's COVID-19 drug	22-11-07	RE
Cantor Fitzgerald Adjusts Veru's Price Target to $30 From $24, Reiterates Overweight Rating	22-08-12	MT
Brookline Capital Markets Adjusts Price Target for Veru to $31 From $29, Reiterates Buy Rating	22-05-18	MT
Jefferies Financial Raises Veru's Price Target to $55 From $33, Maintains Buy Rating	22-05-13	MT
HC Wainwright Adjusts Veru's Price Target to $24 from $21, Keeps Buy Rating	22-04-12	MT
Oppenheimer Adjusts Veru's Price Target to $36 From $25, Maintains Outperform Rating	22-04-12	MT
Oppenheimer Adjusts Veru Price Target to $25 From $26, Maintains Outperform Rating	22-02-10	MT
Veru : Says Phase 1b/2 Trial of Sabizabulin in Prostate Cancer Shows Overall Response Rate of 21%	21-09-20	MT
VERU : Oppenheimer Adjusts Veru PT to $26 From $24, Maintains Outperform Rating	21-08-13	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. Veru Inc.

Equities

VERU

US92536C1036

Analyst Reco.

Filters